{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:27:33Z","timestamp":1791462453736,"version":"4.3.4"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00210-024-03466-0","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:01:49Z","timestamp":1728388909000},"page":"2127-2150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape"],"prefix":"10.1007","volume":"398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-4942","authenticated-orcid":false,"given":"Meghana N.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-8581","authenticated-orcid":false,"given":"Archita J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-4865","authenticated-orcid":false,"given":"Manish N.","family":"Nandpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-2264","authenticated-orcid":false,"given":"Manan A.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8442-0349","authenticated-orcid":false,"given":"Ravish J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8223-9311","authenticated-orcid":false,"given":"Amit A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-2080","authenticated-orcid":false,"given":"Keshav Raj","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-3035","authenticated-orcid":false,"given":"Philip M.","family":"Hansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-6572","authenticated-orcid":false,"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-0229","authenticated-orcid":false,"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-1159","authenticated-orcid":false,"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-8296","authenticated-orcid":false,"given":"Samir G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"3466_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0078791","volume":"8","author":"AA Adane","year":"2013","unstructured":"Adane AA, Alene KA, Koye DN, Zeleke BM (2013) Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in Northwest Ethiopia. PLoS One 8:1\u20136. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0078791","journal-title":"PLoS One"},{"key":"3466_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.4103\/ijmr.IJMR","volume":"76","author":"A Aggarwal","year":"2012","unstructured":"Aggarwal A, Mehta S, Gupta D et al (2012) Clinical & immunological erythematosus patients characteristics in systemic lupus Maryam. J Dent Educ 76:1532\u20131539. https:\/\/doi.org\/10.4103\/ijmr.IJMR","journal-title":"J Dent Educ"},{"key":"3466_CR3","first-page":"263","volume-title":"Springer","author":"F Ahmad Khan","year":"2017","unstructured":"Ahmad Khan F, Fox G, Menzies D (2017) Drug-resistant tuberculosis BT - Handbook of Antimicrobial Resistance. In: Berghuis A, Matlashewski G, Wainberg MA et al (eds) Springer. New York, NY, New York, pp 263\u2013286"},{"key":"3466_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13543776.2022.2012151","volume":"32","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Nandi S, Saxena AK (2022) An updated patent review on drugs for the treatment of tuberculosis (2018-present). Expert Opin Ther Pat 32:243\u2013260. https:\/\/doi.org\/10.1080\/13543776.2022.2012151","journal-title":"Expert Opin Ther Pat"},{"key":"3466_CR5","first-page":"175","volume":"19","author":"J-G Alejandra Isabel","year":"2019","unstructured":"Alejandra Isabel J-G, Miroslava F-P, Rafael L-L (2019) Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Rev Am Med Respir 19:175\u2013178","journal-title":"Rev Am Med Respir"},{"key":"3466_CR6","first-page":"175","volume":"3","author":"J-G Alejandra Isabel","year":"2019","unstructured":"Alejandra Isabel J-G, Miroslava F-P, Rafael L-L (2019) Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Rev Am Med Respir 3:175\u2013178","journal-title":"Rev Am Med Respir"},{"key":"3466_CR7","doi-asserted-by":"publisher","first-page":"e070143","DOI":"10.1136\/bmjopen-2022-070143","volume":"13","author":"A Alemu","year":"2023","unstructured":"Alemu A, Bitew ZW, Diriba G et al (2023) Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis. BMJ Open 13:e070143. https:\/\/doi.org\/10.1136\/bmjopen-2022-070143","journal-title":"BMJ Open"},{"key":"3466_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.16.567434","author":"MZ Ali","year":"2024","unstructured":"Ali MZ, Dutt TS, MacNeill A et al (2024) A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. bioRxiv. https:\/\/doi.org\/10.1101\/2023.11.16.567434","journal-title":"bioRxiv"},{"key":"3466_CR9","unstructured":"Alliance\u00a0Global (2008) Handbook of Anti Tuberculosis Agents, New York, NY. Global Alliance for TB Drug Development 88(2):85\u2013170"},{"key":"3466_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FMICB.2021.612675\/BIBTEX","volume":"12","author":"A Allue-Guardia","year":"2021","unstructured":"Allue-Guardia A, Garc\u00eda JI, Torrelles JB (2021) Evolution of drug-resistant mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol 12:1\u201321. https:\/\/doi.org\/10.3389\/FMICB.2021.612675\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3466_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/ETLS20190154","volume":"4","author":"KH Alzahabi","year":"2020","unstructured":"Alzahabi KH, Usmani O, Georgiou TK et al (2020) Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies. Emerg Top Life Sci 4:581\u2013600. https:\/\/doi.org\/10.1042\/ETLS20190154","journal-title":"Emerg Top Life Sci"},{"key":"3466_CR12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2021) Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes\u20142022. In: Diabetes Care. American Diabetes Association Professional Practice Committee, pp 46\u201359","DOI":"10.2337\/dc22-S004"},{"key":"3466_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","volume":"50","author":"A Aubry","year":"2006","unstructured":"Aubry A, Veziris N, Cambau E et al (2006) Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104\u2013112. https:\/\/doi.org\/10.1128\/AAC.50.1.104-112.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/IJTLD.14.0100","volume":"18","author":"KJM Aung","year":"2014","unstructured":"Aung KJM, Van Deun A, Declercq E et al (2014) Successful \u201c9-month Bangladesh regimen\u201d for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc lung Dis 18:1180\u20131187. https:\/\/doi.org\/10.5588\/IJTLD.14.0100","journal-title":"Int J Tuberc lung Dis"},{"key":"3466_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13756-017-0208-X\/TABLES\/2","volume":"6","author":"JA Ayukekbong","year":"2017","unstructured":"Ayukekbong JA, Ntemgwa M, Atabe AN (2017) The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrob Resist Infect Control 6:1\u20138. https:\/\/doi.org\/10.1186\/S13756-017-0208-X\/TABLES\/2","journal-title":"Antimicrob Resist Infect Control"},{"key":"3466_CR16","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1007\/S11033-022-07404-2\/TABLES\/4","volume":"49","author":"P Bakhtiyariniya","year":"2022","unstructured":"Bakhtiyariniya P, Khosravi AD, Hashemzadeh M, Savari M (2022) Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran. Mol Biol Rep 49:6135\u20136143. https:\/\/doi.org\/10.1007\/S11033-022-07404-2\/TABLES\/4","journal-title":"Mol Biol Rep"},{"key":"3466_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/167954","volume":"2013","author":"Z Bakuba","year":"2013","unstructured":"Bakuba Z, Napi\u00f3rkowska A, Bielecki J et al (2013) Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis clinical isolates from Poland. Biomed Res Int 2013:1\u20135. https:\/\/doi.org\/10.1155\/2013\/167954","journal-title":"Biomed Res Int"},{"key":"3466_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ADTP.202000113","volume":"4","author":"Z Baranyai","year":"2021","unstructured":"Baranyai Z, Soria-Carrera H, Alleva M et al (2021) Nanotechnology-based targeted drug delivery: an emerging tool to overcome tuberculosis. Adv Ther 4:1\u201322. https:\/\/doi.org\/10.1002\/ADTP.202000113","journal-title":"Adv Ther"},{"key":"3466_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/PATHOGENS12080978","volume":"12","author":"M Beviere","year":"2023","unstructured":"Beviere M, Reissier S, Penven M et al (2023) The role of next-generation sequencing (NGS) in the management of tuberculosis: practical review for implementation in routine. Pathogens 12:978. https:\/\/doi.org\/10.3390\/PATHOGENS12080978","journal-title":"Pathogens"},{"key":"3466_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.5588\/ijtld.15.0864","volume":"20","author":"VR Bollela","year":"2017","unstructured":"Bollela VR, Namburete EI, Feliciano CS et al (2017) Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis 20:1099\u20131104. https:\/\/doi.org\/10.5588\/ijtld.15.0864","journal-title":"Int J Tuberc Lung Dis"},{"key":"3466_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/TROPICALMED8020100","volume":"8","author":"K Borah Slater","year":"2023","unstructured":"Borah Slater K, Kim D, Chand P et al (2023) A current perspective on the potential of nanomedicine for anti-tuberculosis therapy. Trop Med Infect Dis 8:100\u2013112. https:\/\/doi.org\/10.3390\/TROPICALMED8020100","journal-title":"Trop Med Infect Dis"},{"key":"3466_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics15020393","volume":"15","author":"T Bourguignon","year":"2023","unstructured":"Bourguignon T, Godinez-Leon JA, Gref R (2023) Nanosized drug delivery systems to fight tuberculosis. Pharmaceutics 15:1\u201342. https:\/\/doi.org\/10.3390\/pharmaceutics15020393","journal-title":"Pharmaceutics"},{"key":"3466_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01299-16","volume":"61","author":"F Brossier","year":"2017","unstructured":"Brossier F, Pham A, Bernard C et al (2017) Molecular investigation of resistance to second-line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61:1\u20139. https:\/\/doi.org\/10.1128\/AAC.01299-16","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1156249","volume":"14","author":"Q Bu","year":"2023","unstructured":"Bu Q, Qiang R, Fang L et al (2023) Global trends in the incidence rates of MDR and XDR tuberculosis: findings from the global burden of disease study 2019. Front Pharmacol 14:1\u20139. https:\/\/doi.org\/10.3389\/fphar.2023.1156249","journal-title":"Front Pharmacol"},{"key":"3466_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3978\/J.ISSN.2072-1439.2013.11.11","volume":"6","author":"GL Calligaro","year":"2014","unstructured":"Calligaro GL, Moodley L, Symons G, Dheda K (2014) The medical and surgical treatment of drug-resistant tuberculosis. J Thorac Dis 6:186\u2013195. https:\/\/doi.org\/10.3978\/J.ISSN.2072-1439.2013.11.11","journal-title":"J Thorac Dis"},{"key":"3466_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1128\/AAC.01550-10","volume":"55","author":"PJ Campbell","year":"2011","unstructured":"Campbell PJ, Morlock GP, Sikes RD et al (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032\u20132041. https:\/\/doi.org\/10.1128\/AAC.01550-10","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR27","unstructured":"CDC (2016a) Fact sheets | drug-resistant TB | extensively drug-resistant tuberculosis (XDR TB) | TB | CDC. In: Cent. Dis. Control Prev. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/drtb\/xdrtb.htm. Accessed 5 Jun 2023"},{"key":"3466_CR28","unstructured":"CDC (2016b) Fact sheets | drug-resistant tb | extensively drug-resistant tuberculosis (XDR TB) | TB | CDC. In: Cent. Dis. Control Prev. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/drtb\/xdrtb.htm. Accessed 26 May 2023"},{"key":"3466_CR29","unstructured":"CDC (2016c) TB diagnostic tool: Xpert MTB\/RIF assay fact sheet | TB | CDC. In: Cell. Mol. Neurobiol. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/testing\/xpert_mtb-rif.htm. Accessed 22 Mar 2024"},{"key":"3466_CR30","unstructured":"CDC (2016d) General Considerations for treatment of TB fact sheet | TB | CDC. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/treatment\/treatmenthivnegative.htm#:~:text=Regimens for treating TB disease,after 2 months of treatment. Accessed 7 Jun 2023"},{"key":"3466_CR31","unstructured":"CDC (2021) Diagnosis of tuberculosis disease. in: core curriculum on tuberculosis: what the clinician should know. Centers for Disease Control and Prevention, pp 75\u2013107"},{"key":"3466_CR32","unstructured":"CDC (2022) Drug-resistant TB | TB |CDC. In: Centers Dis. Control Prev. https:\/\/www.cdc.gov\/tb\/topic\/drtb\/default.htm. Accessed 7 Jun 2023"},{"key":"3466_CR33","unstructured":"CDC (2023) About drug-resistant tuberculosis disease | tuberculosis (TB) | CDC. https:\/\/www.cdc.gov\/tb\/about\/drug-resistant.html. Accessed 7 Aug 2024"},{"key":"3466_CR34","unstructured":"CDC (2024a) Clinical overview of drug-resistant tuberculosis disease | tuberculosis (TB) | CDC. https:\/\/www.cdc.gov\/tb\/hcp\/clinical-overview\/drug-resistant-tuberculosis-disease.html. Accessed 7 Aug 2024"},{"key":"3466_CR35","unstructured":"CDC (2024b) Bedaquiline, pretomanid, and linezolid (BPaL) | TB |CDC. In: Cent. Dis. Control Prev. https:\/\/www.cdc.gov\/tb\/topic\/drtb\/bpal\/default.htm. Accessed 22 Mar 2024"},{"key":"3466_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/J.1440-1843.2010.01738.X","volume":"15","author":"CY Chiang","year":"2010","unstructured":"Chiang CY, Centis R, Migliori GB (2010) Drug-resistant tuberculosis: past, present, future. Respirology 15:413\u2013432. https:\/\/doi.org\/10.1111\/J.1440-1843.2010.01738.X","journal-title":"Respirology"},{"key":"3466_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/PH16040581","volume":"16","author":"H Chopra","year":"2023","unstructured":"Chopra H, Mohanta YK, Rauta PR et al (2023) An insight into advances in developing nanotechnology based therapeutics, drug delivery, diagnostics and vaccines: multidimensional applications in tuberculosis disease management. Pharmaceuticals 16:581\u2013617. https:\/\/doi.org\/10.3390\/PH16040581","journal-title":"Pharmaceuticals"},{"key":"3466_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0119332","volume":"10","author":"K Chung-Delgado","year":"2015","unstructured":"Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A (2015) Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One 10:1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0119332","journal-title":"PLoS One"},{"key":"3466_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02075-21","volume":"66","author":"D Conkle-Gutierrez","year":"2022","unstructured":"Conkle-Gutierrez D, Kim C, Ramirez-Busby SM et al (2022) Distribution of common and rare genetic markers of second-line-injectable-drug resistance in Mycobacterium tuberculosis revealed by a genome-wide association study. Antimicrob Agents Chemother 66:1\u201312. https:\/\/doi.org\/10.1128\/AAC.02075-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/J.JMII.2012.08.020","volume":"46","author":"B Cuevas-C\u00f3rdoba","year":"2013","unstructured":"Cuevas-C\u00f3rdoba B, Cuellar-S\u00e1nchez A, Pasissi-Crivelli A et al (2013) rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. J Microbiol Immunol Infect 46:30\u201334. https:\/\/doi.org\/10.1016\/J.JMII.2012.08.020","journal-title":"J Microbiol Immunol Infect"},{"key":"3466_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/J.MIMET.2020.106127","volume":"181","author":"MH Dahanayake","year":"2021","unstructured":"Dahanayake MH, Jayasundera ACA (2021) Nano-based drug delivery optimization for tuberculosis treatment: a review. J Microbiol Methods 181:106\u2013127. https:\/\/doi.org\/10.1016\/J.MIMET.2020.106127","journal-title":"J Microbiol Methods"},{"key":"3466_CR42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois VA, Rubin EJ (2022) Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol 20:685\u2013701. https:\/\/doi.org\/10.1038\/s41579-022-00731-y","journal-title":"Nat Rev Microbiol"},{"key":"3466_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0248408","volume":"16","author":"M Das","year":"2021","unstructured":"Das M, Mathur T, Ravi S et al (2021) Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: a qualitative study. PLoS One 16:1\u201315. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0248408","journal-title":"PLoS One"},{"key":"3466_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/J.TUBE.2018.08.010","volume":"113","author":"DA da Silva","year":"2018","unstructured":"da Silva DA, Ferreira NV, Rego AM et al (2018) Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates. Tuberculosis 113:163\u2013174. https:\/\/doi.org\/10.1016\/J.TUBE.2018.08.010","journal-title":"Tuberculosis"},{"key":"3466_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/FGENE.2019.00922\/BIBTEX","volume":"10","author":"W Deelder","year":"2019","unstructured":"Deelder W, Christakoudi S, Phelan J et al (2019) Machine learning predicts accurately mycobacterium tuberculosis drug resistance from whole genome sequencing data. Front Genet 10:421\u2013474. https:\/\/doi.org\/10.3389\/FGENE.2019.00922\/BIBTEX","journal-title":"Front Genet"},{"key":"3466_CR46","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1128\/JCM.05286-11","volume":"50","author":"R Devasia","year":"2012","unstructured":"Devasia R, Blackman A, Eden S et al (2012) High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 50:1390\u20131396. https:\/\/doi.org\/10.1128\/JCM.05286-11","journal-title":"J Clin Microbiol"},{"key":"3466_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","volume":"2","author":"K Dheda","year":"2014","unstructured":"Dheda K, Gumbo T, Gandhi NR et al (2014) Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321\u2013338. https:\/\/doi.org\/10.1016\/S2213-2600(14)70031-1","journal-title":"Lancet Respir Med"},{"key":"3466_CR48","doi-asserted-by":"publisher","first-page":"1225438","DOI":"10.3389\/FMICB.2023.1225438\/BIBTEX","volume":"14","author":"M Doh\u00e1l","year":"2023","unstructured":"Doh\u00e1l M, Porvazn\u00edk I, Solovi\u010d I, Mokr\u00fd J (2023) Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine. Front Microbiol 14:1225438. https:\/\/doi.org\/10.3389\/FMICB.2023.1225438\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3466_CR49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/J.IDC.2016.02.011","volume":"30","author":"Y Doi","year":"2016","unstructured":"Doi Y, Wachino JI, Arakawa Y (2016) Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am 30:523\u2013537. https:\/\/doi.org\/10.1016\/J.IDC.2016.02.011","journal-title":"Infect Dis Clin North Am"},{"key":"3466_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/JIN2.61","volume":"4","author":"S Donnellan","year":"2019","unstructured":"Donnellan S, Giardiello M (2019) Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis. J Interdiscip Nanomedicine 4:76\u201385. https:\/\/doi.org\/10.1002\/JIN2.61","journal-title":"J Interdiscip Nanomedicine"},{"key":"3466_CR51","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/JAC\/DKX506","volume":"73","author":"N Dookie","year":"2018","unstructured":"Dookie N, Rambaran S, Padayatchi N et al (2018) Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother 73:1138\u20131151. https:\/\/doi.org\/10.1093\/JAC\/DKX506","journal-title":"J Antimicrob Chemother"},{"key":"3466_CR52","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/CID\/CIAA526","volume":"71","author":"N Dookie","year":"2020","unstructured":"Dookie N, Padayatchi N, Lessells RJ et al (2020) Individualized treatment of multidrug-resistant tuberculosis using whole-genome sequencing and expanded drug-susceptibility testing. Clin Infect Dis 71:2981\u20132985. https:\/\/doi.org\/10.1093\/CID\/CIAA526","journal-title":"Clin Infect Dis"},{"key":"3466_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/CMR.00180-19","volume":"35","author":"N Dookie","year":"2022","unstructured":"Dookie N, Ngema SL, Perumal R et al (2022) The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clin Microbiol Rev 35:180\u2013219. https:\/\/doi.org\/10.1128\/CMR.00180-19","journal-title":"Clin Microbiol Rev"},{"key":"3466_CR54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","volume":"18","author":"SE Dorman","year":"2018","unstructured":"Dorman SE, Schumacher SG, Alland D et al (2018) Xpert MTB\/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(17)30691-6","journal-title":"Lancet Infect Dis"},{"key":"3466_CR55","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/J.CCT.2020.105938","volume":"90","author":"SE Dorman","year":"2020","unstructured":"Dorman SE, Nahid P, Kurbatova EV et al (2020) High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31\/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials 90:105938. https:\/\/doi.org\/10.1016\/J.CCT.2020.105938","journal-title":"Contemp Clin Trials"},{"key":"3466_CR56","doi-asserted-by":"publisher","first-page":"5185896","DOI":"10.1155\/2020\/5185896","volume":"2020","author":"R Eddabra","year":"2020","unstructured":"Eddabra R, Neffa M (2020) Mutations associated with rifampicin resistance in Mycobacterium tuberculosis isolates from Moroccan patients: systematic review. Interdiscip Perspect Infect Dis 2020:5185896. https:\/\/doi.org\/10.1155\/2020\/5185896","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"3466_CR57","doi-asserted-by":"publisher","first-page":"13259","DOI":"10.3390\/IJMS222413259","volume":"22","author":"MA Ejalonibu","year":"2021","unstructured":"Ejalonibu MA, Ogundare SA, Elrashedy AA et al (2021) Drug discovery for Mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci 22:13259. https:\/\/doi.org\/10.3390\/IJMS222413259","journal-title":"Int J Mol Sci"},{"key":"3466_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00506-21","volume":"65","author":"JP Ernest","year":"2021","unstructured":"Ernest JP, Sarathy J, Wang N et al (2021) Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother 65:1\u201317. https:\/\/doi.org\/10.1128\/AAC.00506-21","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR59","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1001\/JAMA.283.19.2537","volume":"283","author":"MA Espinal","year":"2000","unstructured":"Espinal MA, Kim SJ, Suarez PG et al (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537\u20132545. https:\/\/doi.org\/10.1001\/JAMA.283.19.2537","journal-title":"JAMA"},{"key":"3466_CR60","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","volume":"38","author":"D Falzon","year":"2011","unstructured":"Falzon D, Jaramillo E, Sch\u00fcnemann HJ et al (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516\u2013528. https:\/\/doi.org\/10.1183\/09031936.00073611","journal-title":"Eur Respir J"},{"key":"3466_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JPM13040599\/S1","volume":"13","author":"L Freimane","year":"2023","unstructured":"Freimane L, Bark\u0101ne L, Kivrane A et al (2023) Assessment of amikacin- and capreomycin-related adverse drug reactions in patients with multidrug-resistant tuberculosis and exploring the role of genetic factors. J Pers Med 13:1\u201312. https:\/\/doi.org\/10.3390\/JPM13040599\/S1","journal-title":"J Pers Med"},{"key":"3466_CR62","doi-asserted-by":"publisher","unstructured":"Gairola A, Benjamin A, Weatherston JD, et al (2022) Recent developments in drug delivery for treatment of tuberculosis by targeting macrophages. Adv Ther 5:1\u201349. https:\/\/doi.org\/10.1002\/ADTP.202100193","DOI":"10.1002\/ADTP.202100193"},{"key":"3466_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01350-2018","volume":"52","author":"NR Gandhi","year":"2018","unstructured":"Gandhi NR, Brust JCM, Shah NS (2018) A new era for treatment of drug-resistant tuberculosis. Eur Respir Rev 52:1\u20134. https:\/\/doi.org\/10.1183\/13993003.01350-2018","journal-title":"Eur Respir Rev"},{"key":"3466_CR64","unstructured":"GE2P2 Global Foundation (2024) The sentinel health, human rights, humanitarian action, hertiage-education, climate-environment, development, peace"},{"key":"3466_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0033275","volume":"7","author":"SB Georghiou","year":"2012","unstructured":"Georghiou SB, Magana M, Garfein RS et al (2012) Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:1\u201312. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0033275","journal-title":"PLoS One"},{"key":"3466_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5588\/IJTLD.22.0687","volume":"27","author":"C Geric","year":"2023","unstructured":"Geric C, Qin ZZ, Denkinger CM et al (2023) The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination. Int J Tuberc Lung Dis 27:367\u2013372. https:\/\/doi.org\/10.5588\/IJTLD.22.0687","journal-title":"Int J Tuberc Lung Dis"},{"key":"3466_CR67","doi-asserted-by":"publisher","first-page":"210149","DOI":"10.1183\/20734735.0149-2021","volume":"18","author":"CM Gill","year":"2022","unstructured":"Gill CM, Dolan L, Piggott LM, McLaughlin AM (2022) New developments in tuberculosis diagnosis and treatment. Breathe 18:210149. https:\/\/doi.org\/10.1183\/20734735.0149-2021","journal-title":"Breathe"},{"key":"3466_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/0970-0218.43238","volume":"33","author":"GS Grover","year":"2008","unstructured":"Grover GS, Takkar J (2008) Recent advances in multi-drug-resistant tuberculosis and RNTCP. Indian J Community Med 33:219\u2013223. https:\/\/doi.org\/10.4103\/0970-0218.43238","journal-title":"Indian J Community Med"},{"key":"3466_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01935-2019","volume":"55","author":"L Guglielmetti","year":"2020","unstructured":"Guglielmetti L, Huerga H, Khan U, Varaine F (2020) WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion? Eur Respir J 55:1\u20134. https:\/\/doi.org\/10.1183\/13993003.01935-2019","journal-title":"Eur Respir J"},{"key":"3466_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/IDR.S230774","volume":"13","author":"HMA Hameed","year":"2020","unstructured":"Hameed HMA, Tan Y, Islam MM et al (2020) Detection of novel gene mutations associated with pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates in Southern China. Infect Drug Resist 13:217\u2013227. https:\/\/doi.org\/10.2147\/IDR.S230774","journal-title":"Infect Drug Resist"},{"key":"3466_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01307-x","volume":"20","author":"S He","year":"2022","unstructured":"He S, Gui J, Xiong K et al (2022) A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnology 20:1\u201322. https:\/\/doi.org\/10.1186\/s12951-022-01307-x","journal-title":"J Nanobiotechnology"},{"key":"3466_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/1886.2021.00021","volume":"12","author":"M Heidary","year":"2022","unstructured":"Heidary M, Shirani M, Moradi M et al (2022) Tuberculosis challenges: resistance, co-infection, diagnosis, and treatment. Eur J Microbiol Immunol 12:1\u201317. https:\/\/doi.org\/10.1556\/1886.2021.00021","journal-title":"Eur J Microbiol Immunol"},{"key":"3466_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2049936119864737","volume":"6","author":"J Huynh","year":"2019","unstructured":"Huynh J, Marais BJ (2019) Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis 6:1\u201316. https:\/\/doi.org\/10.1177\/2049936119864737","journal-title":"Ther Adv Infect Dis"},{"key":"3466_CR74","volume-title":"Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis","author":"Institute of Medicine (US)","year":"2013","unstructured":"Institute of Medicine (US) (2013) Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis. National Academies Press, US"},{"key":"3466_CR75","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/J.IJID.2015.01.006","volume":"32","author":"K Jabeen","year":"2015","unstructured":"Jabeen K, Shakoor S, Hasan R (2015) Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis 32:118\u2013123. https:\/\/doi.org\/10.1016\/J.IJID.2015.01.006","journal-title":"Int J Infect Dis"},{"key":"3466_CR76","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/S12038-008-0078-8","volume":"33","author":"A Jain","year":"2008","unstructured":"Jain A, Dixit P (2008) Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J Biosci 33:605\u2013616. https:\/\/doi.org\/10.1007\/S12038-008-0078-8","journal-title":"J Biosci"},{"key":"3466_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-020-62368-2","volume":"10","author":"S Jamal","year":"2020","unstructured":"Jamal S, Khubaib M, Gangwar R et al (2020) Artificial intelligence and machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. Sci Rep 10:1\u201316. https:\/\/doi.org\/10.1038\/S41598-020-62368-2","journal-title":"Sci Rep"},{"key":"3466_CR78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12701\/yujm.2020.00626","volume":"37","author":"JG Jang","year":"2020","unstructured":"Jang JG, Chung JH (2020) Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam Univ J Med 37:277\u2013285","journal-title":"Yeungnam Univ J Med"},{"key":"3466_CR79","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4046\/TRD.2017.0049","volume":"80","author":"D Jeon","year":"2017","unstructured":"Jeon D (2017) WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis (Seoul) 80:336\u2013343. https:\/\/doi.org\/10.4046\/TRD.2017.0049","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"3466_CR80","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/J.RMED.2012.10.021","volume":"107","author":"KW Jo","year":"2013","unstructured":"Jo KW, Ji W, Hong Y et al (2013) The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 107:292\u2013297. https:\/\/doi.org\/10.1016\/J.RMED.2012.10.021","journal-title":"Respir Med"},{"key":"3466_CR81","doi-asserted-by":"publisher","first-page":"e60280","DOI":"10.7759\/CUREUS.60280","volume":"16","author":"K Sp","year":"2024","unstructured":"K SP, Mani AP, Geethalakshmi S, Yadav S (2024) Advancements in artificial intelligence for the diagnosis of multidrug resistance and extensively drug-resistant tuberculosis: a comprehensive review. Cureus 16:e60280. https:\/\/doi.org\/10.7759\/CUREUS.60280","journal-title":"Cureus"},{"key":"3466_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12890-020-1172-4\/FIGURES\/2","volume":"20","author":"S Kabir","year":"2020","unstructured":"Kabir S, Tahir Z, Mukhtar N et al (2020) Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulm Med 20:1\u20136. https:\/\/doi.org\/10.1186\/S12890-020-1172-4\/FIGURES\/2","journal-title":"BMC Pulm Med"},{"key":"3466_CR83","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3201\/EID2106.141873","volume":"21","author":"RR Kempker","year":"2015","unstructured":"Kempker RR, Kipiani M, Mirtskhulava V et al (2015) Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg Infect Dis 21:992\u20131001. https:\/\/doi.org\/10.3201\/EID2106.141873","journal-title":"Emerg Infect Dis"},{"key":"3466_CR84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5588\/IJTLD.18.0217","volume":"23","author":"EA Kendall","year":"2019","unstructured":"Kendall EA, Sahu S, Pai M et al (2019) What will it take to eliminate drug-resistant tuberculosis? Int J Tuberc Lung Dis 23:535\u2013546. https:\/\/doi.org\/10.5588\/IJTLD.18.0217","journal-title":"Int J Tuberc Lung Dis"},{"key":"3466_CR85","doi-asserted-by":"publisher","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","volume":"50","author":"FA Khan","year":"2017","unstructured":"Khan FA, Salim MAH, du Cros P et al (2017) Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 50:1700061. https:\/\/doi.org\/10.1183\/13993003.00061-2017","journal-title":"Eur Respir J"},{"key":"3466_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.CIMID.2020.101574","volume":"74","author":"JL Khawbung","year":"2021","unstructured":"Khawbung JL, Nath D, Chakraborty S (2021) Drug resistant tuberculosis: a review. Comp Immunol Microbiol Infect Dis 74:1\u20139. https:\/\/doi.org\/10.1016\/J.CIMID.2020.101574","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"3466_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4314\/MMJ.V30I1.1","volume":"30","author":"GP Kumwenda","year":"2018","unstructured":"Kumwenda GP, Chipungu G, Sloan DJ et al (2018) The occurrence and frequency of genomic mutations that mediate isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolates from untreated pulmonary tuberculosis cases in urban Blantyre, Malawi. Malawi Med J 30:1\u20135. https:\/\/doi.org\/10.4314\/MMJ.V30I1.1","journal-title":"Malawi Med J"},{"key":"3466_CR88","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4103\/JFMPC.JFMPC_1787_20","volume":"10","author":"S Kundu","year":"2021","unstructured":"Kundu S, Basu R, Sarkar S et al (2021) Psychological profile of multi drug resistance TB patients: a qualitative study from a Tertiary care Centre of Kolkata. J Fam Med Prim Care 10:392\u2013397. https:\/\/doi.org\/10.4103\/JFMPC.JFMPC_1787_20","journal-title":"J Fam Med Prim Care"},{"key":"3466_CR89","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/S2213-2600(23)00426-5","volume":"12","author":"SM Labuda","year":"2024","unstructured":"Labuda SM, Seaworth B, Dasgupta S, Goswami ND (2024) Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med 12:e5\u2013e6. https:\/\/doi.org\/10.1016\/S2213-2600(23)00426-5","journal-title":"Lancet Respir Med"},{"key":"3466_CR90","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4314\/tjpr.v15i1.28","volume":"15","author":"M Laghari","year":"2016","unstructured":"Laghari M, Darwis Y, Memon AH et al (2016) Nanoformulations and clinical trial candidates as probably effective and safe therapy for tuberculosis. Trop J Pharm Res 15:201\u2013211. https:\/\/doi.org\/10.4314\/tjpr.v15i1.28","journal-title":"Trop J Pharm Res"},{"key":"3466_CR91","doi-asserted-by":"publisher","first-page":"101","DOI":"10.47738\/IJAIM.V3I2.55","volume":"3","author":"J Lai","year":"2023","unstructured":"Lai J (2023) Developing a predictive information system for determining the prognosis of HIV and tuberculosis co-infection in incarcerated individuals. Int J Appl Inf Manag 3:101\u2013110. https:\/\/doi.org\/10.47738\/IJAIM.V3I2.55","journal-title":"Int J Appl Inf Manag"},{"key":"3466_CR92","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5588\/IJTLD.18.0622","volume":"23","author":"C Lange","year":"2019","unstructured":"Lange C, Aarnoutse RE, Alffenaar JWC et al (2019) Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 23:645\u2013662. https:\/\/doi.org\/10.5588\/IJTLD.18.0622","journal-title":"Int J Tuberc Lung Dis"},{"key":"3466_CR93","doi-asserted-by":"publisher","first-page":"10695","DOI":"10.3390\/APP112210695","volume":"11","author":"H Le","year":"2021","unstructured":"Le H, Karakasyan C, Jouenne T et al (2021) Application of polymeric nanocarriers for enhancing the bioavailability of antibiotics at the target site and overcoming antimicrobial resistance. Appl Sci 11:10695\u201310728. https:\/\/doi.org\/10.3390\/APP112210695","journal-title":"Appl Sci"},{"key":"3466_CR94","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1128\/AAC.48.11.4447-4449.2004\/FORMAT\/EPUB","volume":"48","author":"ASG Lee","year":"2004","unstructured":"Lee ASG, Othman SNK, Ho YM, Wong SY (2004) Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48:4447\u20134449. https:\/\/doi.org\/10.1128\/AAC.48.11.4447-4449.2004\/FORMAT\/EPUB","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR95","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/J.ARBRES.2019.11.015","volume":"56","author":"E Letang","year":"2020","unstructured":"Letang E, Ellis J, Naidoo K et al (2020) Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out. Arch Bronconeumol 56:446\u2013454. https:\/\/doi.org\/10.1016\/J.ARBRES.2019.11.015","journal-title":"Arch Bronconeumol"},{"key":"3466_CR96","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.apsb.2019.08.003","volume":"9","author":"C Li","year":"2019","unstructured":"Li C, Wang J, Wang Y et al (2019) Recent progress in drug delivery. Acta Pharm Sin B 9:1145\u20131162. https:\/\/doi.org\/10.1016\/j.apsb.2019.08.003","journal-title":"Acta Pharm Sin B"},{"key":"3466_CR97","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/DDR.21498","volume":"80","author":"Y Li","year":"2019","unstructured":"Li Y, Sun F, Zhang W (2019) Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res 80:98\u2013105. https:\/\/doi.org\/10.1002\/DDR.21498","journal-title":"Drug Dev Res"},{"key":"3466_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FMED.2022.935080\/BIBTEX","volume":"9","author":"S Liang","year":"2022","unstructured":"Liang S, Ma J, Wang G et al (2022) The application of artificial intelligence in the diagnosis and drug resistance prediction of pulmonary tuberculosis. Front Med 9:1\u201314. https:\/\/doi.org\/10.3389\/FMED.2022.935080\/BIBTEX","journal-title":"Front Med"},{"key":"3466_CR99","doi-asserted-by":"publisher","first-page":"943545","DOI":"10.3389\/FCIMB.2022.943545","volume":"12","author":"D Liebenberg","year":"2022","unstructured":"Liebenberg D, Gordhan BG, Kana BD (2022) Drug resistant tuberculosis: implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol 12:943545. https:\/\/doi.org\/10.3389\/FCIMB.2022.943545","journal-title":"Front Cell Infect Microbiol"},{"key":"3466_CR100","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/J.CCA.2022.06.020","volume":"533","author":"M Lin","year":"2022","unstructured":"Lin M, Chen YW, Li YR et al (2022) Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clin Chim Acta 533:183\u2013218. https:\/\/doi.org\/10.1016\/J.CCA.2022.06.020","journal-title":"Clin Chim Acta"},{"key":"3466_CR101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1183\/09031936.00027612","volume":"40","author":"R Loddenkemper","year":"2012","unstructured":"Loddenkemper R, Sotgiu G, Mitnick CD (2012) Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 40:9\u201311. https:\/\/doi.org\/10.1183\/09031936.00027612","journal-title":"Eur Respir J"},{"key":"3466_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.01558-2016","volume":"49","author":"P Lu","year":"2017","unstructured":"Lu P, Liu Q, Martinez L et al (2017) Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J 49:1\u20134. https:\/\/doi.org\/10.1183\/13993003.01558-2016","journal-title":"Eur Respir J"},{"key":"3466_CR103","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2147\/IDR.S207259","volume":"12","author":"M Luo","year":"2019","unstructured":"Luo M, Li K, Zhang H et al (2019) Molecular characterization of para-aminosalicylic acid resistant Mycobacterium tuberculosis clinical isolates in southwestern China. Infect Drug Resist 12:2269\u20132275. https:\/\/doi.org\/10.2147\/IDR.S207259","journal-title":"Infect Drug Resist"},{"key":"3466_CR104","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1042\/ETLS20200335","volume":"4","author":"M MacGregor-Fairlie","year":"2020","unstructured":"MacGregor-Fairlie M, Wilkinson S, Besra GS, Oppenheimer PG (2020) Tuberculosis diagnostics: overcoming ancient challenges with modern solutions. Emerg Top Life Sci 4:435\u2013448. https:\/\/doi.org\/10.1042\/ETLS20200335","journal-title":"Emerg Top Life Sci"},{"key":"3466_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-1068.1000222","volume":"6","author":"LA Malinga","year":"2016","unstructured":"Malinga LA, Stoltz A, Van Der Walt M (2016) Efflux pump mediated second-line tuberculosis drug resistance. Mycobact Dis 6:1\u20139. https:\/\/doi.org\/10.4172\/2161-1068.1000222","journal-title":"Mycobact Dis"},{"key":"3466_CR106","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5588\/IJTLD.12.0198","volume":"17","author":"MT Marrone","year":"2013","unstructured":"Marrone MT, Venkataramanan V, Goodman M et al (2013) Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 17:6\u201316. https:\/\/doi.org\/10.5588\/IJTLD.12.0198","journal-title":"Int J Tuberc Lung Dis"},{"key":"3466_CR107","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccm.2019.08.002","volume":"40","author":"SR Mase","year":"2019","unstructured":"Mase SR, Chorba T (2019) Treatment of drug-resistant tuberculosis. Clin Chest Med 40:775\u2013795. https:\/\/doi.org\/10.1016\/j.ccm.2019.08.002","journal-title":"Clin Chest Med"},{"key":"3466_CR108","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/AAC.49.2.571-577.2005","volume":"49","author":"CE Maus","year":"2005","unstructured":"Maus CE, Plikaytis BB, Shinnick TM (2005) Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:571\u2013577. https:\/\/doi.org\/10.1128\/AAC.49.2.571-577.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR109","doi-asserted-by":"publisher","first-page":"e26297","DOI":"10.1016\/J.HELIYON.2024.E26297","volume":"10","author":"C Mennella","year":"2024","unstructured":"Mennella C, Maniscalco U, De Pietro G, Esposito M (2024) Ethical and regulatory challenges of AI technologies in healthcare: a narrative review. Heliyon 10:e26297. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E26297","journal-title":"Heliyon"},{"key":"3466_CR110","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3389\/FMICB.2020.618168\/BIBTEX","volume":"11","author":"A Minias","year":"2021","unstructured":"Minias A, Zukowska L, Lechowicz E et al (2021) Early drug development and evaluation of putative antitubercular compounds in the -omics era. Front Microbiol 11:3640\u20133656. https:\/\/doi.org\/10.3389\/FMICB.2020.618168\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3466_CR111","unstructured":"Ministry of Health and Family Welfare (2021) Guidelines for programmatic management of drug resistant tuberculosis in India"},{"key":"3466_CR112","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/RESP.13393","volume":"23","author":"P Miotto","year":"2018","unstructured":"Miotto P, Zhang Y, Cirillo DM, Yam WC (2018) Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology 23:1098\u20131113. https:\/\/doi.org\/10.1111\/RESP.13393","journal-title":"Respirology"},{"issue":"20","key":"3466_CR113","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"202","author":"MJ Mitchell","year":"2020","unstructured":"Mitchell MJ, Billingsley MM, Haley RM et al (2020) (2020) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 202(20):101\u2013124. https:\/\/doi.org\/10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discov"},{"key":"3466_CR114","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/IJPVM.IJPVM_114_19","volume":"11","author":"B Mohammadi","year":"2020","unstructured":"Mohammadi B, Ramazanzadeh R, Nouri B, Rouhi S (2020) Frequency of codon 306 mutations in embB gene of Mycobacterium tuberculosis resistant to ethambutol: a systematic review and meta-analysis. Int J Prev Med 11:112\u2013122. https:\/\/doi.org\/10.4103\/IJPVM.IJPVM_114_19","journal-title":"Int J Prev Med"},{"key":"3466_CR115","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1183\/16000617.0080-2015","volume":"25","author":"R Moodley","year":"2016","unstructured":"Moodley R, Godec TR (2016) Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 25:29\u201335. https:\/\/doi.org\/10.1183\/16000617.0080-2015","journal-title":"Eur Respir Rev"},{"key":"3466_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-11-19\/TABLES\/3","volume":"11","author":"PK Moonan","year":"2011","unstructured":"Moonan PK, Quitugua TN, Pogoda JM et al (2011) Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 11:1\u20138. https:\/\/doi.org\/10.1186\/1471-2458-11-19\/TABLES\/3","journal-title":"BMC Public Health"},{"key":"3466_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JOR2010001","volume":"2","author":"CA Moran","year":"2021","unstructured":"Moran CA, Aaina M, Venkatesh K et al (2021) Risk factors and treatment outcome analysis associated with second-line drug-resistant tuberculosis. J Respir 2:1\u201312. https:\/\/doi.org\/10.3390\/JOR2010001","journal-title":"J Respir"},{"key":"3466_CR118","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4314\/AHS.V15I2.9","volume":"15","author":"W Mulu","year":"2015","unstructured":"Mulu W, Mekonnen D, Yimer M et al (2015) Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci 15:368\u2013377. https:\/\/doi.org\/10.4314\/AHS.V15I2.9","journal-title":"Afr Health Sci"},{"key":"3466_CR119","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1513\/ANNALSATS.201509-632PS","volume":"12","author":"JF Murray","year":"2015","unstructured":"Murray JF, Schraufnagel DE, Hopewell PC (2015) Treatment of tuberculosis. a historical perspective. Ann Am Thorac Soc 12:1749\u20131759. https:\/\/doi.org\/10.1513\/ANNALSATS.201509-632PS","journal-title":"Ann Am Thorac Soc"},{"key":"3466_CR120","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/S13346-020-00786-5\/TABLES\/6","volume":"10","author":"B Nabi","year":"2020","unstructured":"Nabi B, Rehman S, Aggarwal S et al (2020) Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention. Drug Deliv Transl Res 10:1111\u20131121. https:\/\/doi.org\/10.1007\/S13346-020-00786-5\/TABLES\/6","journal-title":"Drug Deliv Transl Res"},{"key":"3466_CR121","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1164\/RCCM.201909-1874ST","volume":"200","author":"P Nahid","year":"2024","unstructured":"Nahid P, Mase SR, Migliori GB et al (2024) Treatment of drug-resistant tuberculosis an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 200:E93\u2013E142. https:\/\/doi.org\/10.1164\/RCCM.201909-1874ST","journal-title":"Am J Respir Crit Care Med"},{"key":"3466_CR122","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/PATHOGENS13010027","volume":"13","author":"K Naidoo","year":"2023","unstructured":"Naidoo K, Perumal R, Ngema SL et al (2023) Rapid diagnosis of drug-resistant tuberculosis\u2013opportunities and challenges. Pathogens 13:27. https:\/\/doi.org\/10.3390\/PATHOGENS13010027","journal-title":"Pathogens"},{"key":"3466_CR123","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.2147\/IDR.S381643","volume":"15","author":"L Nandlal","year":"2022","unstructured":"Nandlal L, Perumal R, Naidoo K (2022) Rapid molecular assays for the diagnosis of drug-resistant tuberculosis. Infect Drug Resist 15:4971\u20134984. https:\/\/doi.org\/10.2147\/IDR.S381643","journal-title":"Infect Drug Resist"},{"key":"3466_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4920209","volume":"2017","author":"M Nasiruddin","year":"2017","unstructured":"Nasiruddin M, Neyaz MK, Das S (2017) Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat 2017:1\u201312. https:\/\/doi.org\/10.1155\/2017\/4920209","journal-title":"Tuberc Res Treat"},{"key":"3466_CR125","doi-asserted-by":"publisher","first-page":"103939","DOI":"10.1016\/J.EBIOM.2022.103939","volume":"78","author":"RR Nathavitharana","year":"2022","unstructured":"Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M et al (2022) Reimagining the status quo: how close are we to rapid sputum-free tuberculosis diagnostics for all? eBioMedicine 78:103939. https:\/\/doi.org\/10.1016\/J.EBIOM.2022.103939","journal-title":"eBioMedicine"},{"key":"3466_CR126","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","volume":"22","author":"N Ndjeka","year":"2022","unstructured":"Ndjeka N, Campbell JR, Meintjes G et al (2022) Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis 22:1042\u20131051. https:\/\/doi.org\/10.1016\/S1473-3099(21)00811-2","journal-title":"Lancet Infect Dis"},{"key":"3466_CR127","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3390\/PATHOGENS11111343","volume":"11","author":"TE Ness","year":"2022","unstructured":"Ness TE, DiNardo A, Farhat MR (2022) High throughput sequencing for clinical tuberculosis: an overview. Pathogens 11:1343. https:\/\/doi.org\/10.3390\/PATHOGENS11111343","journal-title":"Pathogens"},{"key":"3466_CR128","unstructured":"NITI Ayog (2018) National strategy for artificial intelligence, India, 1\u2013114"},{"key":"3466_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0255357","volume":"16","author":"NB Ngoc","year":"2021","unstructured":"Ngoc NB, Dinh HV, Thuy NT et al (2021) Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam. PLoS One 16:1\u201313. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0255357","journal-title":"PLoS One"},{"key":"3466_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FMICB.2019.00794\/FULL","volume":"10","author":"TNA Nguyen","year":"2019","unstructured":"Nguyen TNA, Le Berre VA, Ba\u00f1uls AL, Nguyen TVA (2019) Molecular diagnosis of drug-resistant tuberculosis; a literature review. Front Microbiol 10:1\u201312. https:\/\/doi.org\/10.3389\/FMICB.2019.00794\/FULL","journal-title":"Front Microbiol"},{"key":"3466_CR131","doi-asserted-by":"publisher","unstructured":"Nogueira BMF, Krishnan S, Barreto\u2010Duarte B, et al (2022) Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Mol Med 14:14088. https:\/\/doi.org\/10.15252\/EMMM.202114088","DOI":"10.15252\/EMMM.202114088"},{"key":"3466_CR132","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4046\/TRD.2021.0122","volume":"85","author":"A Oehadian","year":"2022","unstructured":"Oehadian A, Santoso P, Menzies D, Ruslami R (2022) Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria. Tuberc Respir Dis (Seoul) 85:111. https:\/\/doi.org\/10.4046\/TRD.2021.0122","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"3466_CR133","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/JAC\/DKV354","volume":"71","author":"ID Olaru","year":"2016","unstructured":"Olaru ID, Lange C, Heyckendorf J (2016) Personalized medicine for patients with MDR-TB. J Antimicrob Chemother 71:852\u2013855. https:\/\/doi.org\/10.1093\/JAC\/DKV354","journal-title":"J Antimicrob Chemother"},{"key":"3466_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0250028","volume":"16","author":"O Oliveira","year":"2021","unstructured":"Oliveira O, Gaio R, Correia-Neves M et al (2021) Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000\u20132016. PLoS One 16:1\u201313. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0250028","journal-title":"PLoS One"},{"key":"3466_CR135","unstructured":"Olson S, English R, Claiborne A (2011) Transmission and infection control of drug-resistant TB. In: The new profile of drug-resistant tuberculosis in Russia: a global and local perspective: summary of a joint workshop. National Academies Press (US), Washington (DC), pp 37\u201347"},{"key":"3466_CR136","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/CID\/CIAC528","volume":"76","author":"C Padmapriyadarsini","year":"2023","unstructured":"Padmapriyadarsini C, Vohra V, Bhatnagar A et al (2023) Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis An Off Publ Infect Dis Soc Am 76:e938. https:\/\/doi.org\/10.1093\/CID\/CIAC528","journal-title":"Clin Infect Dis An Off Publ Infect Dis Soc Am"},{"key":"3466_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/CUREUS.30764","volume":"14","author":"E Paikray","year":"2022","unstructured":"Paikray E, Das P, Pattnaik M, Mishra V (2022) Adverse drug reaction monitoring in multidrug-resistant tuberculosis patients receiving bedaquiline and delamanid-based regimen. Cureus 14:1\u20138. https:\/\/doi.org\/10.7759\/CUREUS.30764","journal-title":"Cureus"},{"key":"3466_CR138","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/ANTIBIOTICS3030317","volume":"3","author":"JC Palomino","year":"2014","unstructured":"Palomino JC, Martin A (2014) Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics 3:317. https:\/\/doi.org\/10.3390\/ANTIBIOTICS3030317","journal-title":"Antibiotics"},{"key":"3466_CR139","doi-asserted-by":"publisher","first-page":"e32976","DOI":"10.1371\/journal.pone.0032976","volume":"7","author":"Y Pang","year":"2012","unstructured":"Pang Y, Zhou Y, Zhao B et al (2012) Spoligotyping and drug resistance analysis of Mycobacterium Tuberculosis strains from national survey in China. PLoS One 7:e32976. https:\/\/doi.org\/10.1371\/journal.pone.0032976","journal-title":"PLoS One"},{"key":"3466_CR140","volume-title":"Out of step 2015 TB policies in 24 countries A survey of diagnostic and treatment practices","author":"ST Partnership","year":"2015","unstructured":"Partnership ST (2015) Out of step 2015 TB policies in 24 countries A survey of diagnostic and treatment practices. Switzerland, Geneva"},{"key":"3466_CR141","unstructured":"PatSeer (2023) Patent Search. https:\/\/patseer.com\/category\/patent-search\/. Accessed 11 Jun 2023"},{"key":"3466_CR142","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MCP.0000000000000477","volume":"24","author":"E Pontali","year":"2018","unstructured":"Pontali E, Visca D, Centis R et al (2018) Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med 24:244\u2013252. https:\/\/doi.org\/10.1097\/MCP.0000000000000477","journal-title":"Curr Opin Pulm Med"},{"key":"3466_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/16000617.0035-2019","volume":"28","author":"E Pontali","year":"2019","unstructured":"Pontali E, Raviglione MC, Migliori GB et al (2019) Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev 28:1\u20137. https:\/\/doi.org\/10.1183\/16000617.0035-2019","journal-title":"Eur Respir Rev"},{"key":"3466_CR144","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1128\/AAC.44.9.2233-2241.2000","volume":"44","author":"K Poole","year":"2000","unstructured":"Poole K (2000) Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother 44:2233\u20132241. https:\/\/doi.org\/10.1128\/AAC.44.9.2233-2241.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR145","doi-asserted-by":"publisher","first-page":"e03462","DOI":"10.1128\/SPECTRUM.03462-23","volume":"12","author":"A Prommi","year":"2024","unstructured":"Prommi A, Wongjarit K, Petsong S et al (2024) Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. Microbiol Spectr 12:e03462-23. https:\/\/doi.org\/10.1128\/SPECTRUM.03462-23","journal-title":"Microbiol Spectr"},{"key":"3466_CR146","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/lungindia.lungindia","volume":"35","author":"NG Rajendra Prasad","year":"2018","unstructured":"Rajendra Prasad NG (2018) Multidrug-resistant tuberculosis\/rifampicin-resistant tuberculosis: principles and management. Lung India 35:78\u201381. https:\/\/doi.org\/10.4103\/lungindia.lungindia","journal-title":"Lung India"},{"key":"3466_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FPHAR.2021.749945\/BIBTEX","volume":"12","author":"A Rajput","year":"2021","unstructured":"Rajput A, Mandlik S, Pokharkar V (2021) Nanocarrier-based approaches for the efficient delivery of anti-tubercular drugs and vaccines for management of tuberculosis. Front Pharmacol 12:1\u20139. https:\/\/doi.org\/10.3389\/FPHAR.2021.749945\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"3466_CR148","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1128\/AAC.02191-12","volume":"57","author":"AZ Reeves","year":"2013","unstructured":"Reeves AZ, Campbell PJ, Sultana R et al (2013) Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5\u2032 untranslated region of whiB7. Antimicrob Agents Chemother 57:1857\u20131865. https:\/\/doi.org\/10.1128\/AAC.02191-12","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR149","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.jctube.2020.100156","volume":"19","author":"MJA Reid","year":"2020","unstructured":"Reid MJA, Goosby E (2020) Improving quality is necessary to building a TB-free world: Lancet Commission on Tuberculosis. J Clin Tuberc Other Mycobact Dis 19:100156. https:\/\/doi.org\/10.1016\/j.jctube.2020.100156","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"3466_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/FEMSRE\/FUAB050","volume":"46","author":"S Remm","year":"2022","unstructured":"Remm S, Earp JC, Dick T et al (2022) Critical discussion on drug efflux in Mycobacterium tuberculosis. FEMS Microbiol Rev 46:1\u201315. https:\/\/doi.org\/10.1093\/FEMSRE\/FUAB050","journal-title":"FEMS Microbiol Rev"},{"key":"3466_CR151","unstructured":"Revised National Tuberculosis Control Programme (2012) Guidelines on programmatic management of drug resistant TB (PMDT) in India control programme guidelines on programmatic management of drug resistant TB ( PMDT ) in India. New Delhi"},{"key":"3466_CR152","unstructured":"Revised National Tuberculosis Control Programme (2017) National Strategic Plan For Tuberculosis: 2017-25 Elimination By 2025. New Delhi, India, 1\u2013144"},{"key":"3466_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13104-023-06394-Z\/TABLES\/1","volume":"16","author":"L Rigouts","year":"2023","unstructured":"Rigouts L, Keysers J, Rabab R et al (2023) GeneXpert MTB\/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis. BMC Res Notes 16:1\u20135. https:\/\/doi.org\/10.1186\/S13104-023-06394-Z\/TABLES\/1","journal-title":"BMC Res Notes"},{"key":"3466_CR154","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/JOX11040013","volume":"11","author":"M Saha","year":"2021","unstructured":"Saha M, Sarkar A (2021) Review on multiple facets of drug resistance: a rising challenge in the 21st century. J Xenobiotics 11:197\u2013214. https:\/\/doi.org\/10.3390\/JOX11040013","journal-title":"J Xenobiotics"},{"key":"3466_CR155","unstructured":"Sahra S (2024a) Tuberculosis (TB) Differential diagnoses. In: MedScape. https:\/\/emedicine.medscape.com\/article\/230802-differential. Accessed 7 Aug 2024"},{"key":"3466_CR156","unstructured":"Sahra S (2024b) Tuberculosis (TB) treatment & management: approach considerations, treatment during pregnancy, treatment in children. In: MedScape. https:\/\/emedicine.medscape.com\/article\/230802-treatment. Accessed 7 Aug 2024"},{"key":"3466_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JCTUBE.2019.100093","volume":"15","author":"S Salehitali","year":"2019","unstructured":"Salehitali S, Noorian K, Hafizi M, Dehkordi AH (2019) Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis 15:1\u20134. https:\/\/doi.org\/10.1016\/J.JCTUBE.2019.100093","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"3466_CR158","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/GENES14061231","volume":"14","author":"C Sava","year":"2023","unstructured":"Sava C, Sava M, Dr\u0103gan AM et al (2023) The use of Xpert MTB\/RIF ultra testing for early diagnosis of tuberculosis: a retrospective study from a single-center database. Genes 14:1231. https:\/\/doi.org\/10.3390\/GENES14061231","journal-title":"Genes"},{"key":"3466_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML (2015a) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5:1\u201320. https:\/\/doi.org\/10.1101\/cshperspect.a017863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3466_CR160","first-page":"1","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML (2015b) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Lab Press 5:1\u201321","journal-title":"Cold Spring Harb Lab Press"},{"key":"3466_CR161","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/IJMR.IJMR_579_19","volume":"149","author":"SK Sharma","year":"2019","unstructured":"Sharma SK, Dheda K (2019) What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment? Indian J Med Res 149:309\u2013312. https:\/\/doi.org\/10.4103\/IJMR.IJMR_579_19","journal-title":"Indian J Med Res"},{"key":"3466_CR162","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1021\/ACSOMEGA.2C05511\/SUPPL_FILE\/AO2C05511_SI_001.PDF","volume":"8","author":"K Sharma","year":"2023","unstructured":"Sharma K, Ahmed F, Sharma T et al (2023) Potential repurposed drug candidates for tuberculosis treatment: progress and update of drugs identified in over a decade. ACS Omega 8:17362\u201317380. https:\/\/doi.org\/10.1021\/ACSOMEGA.2C05511\/SUPPL_FILE\/AO2C05511_SI_001.PDF","journal-title":"ACS Omega"},{"key":"3466_CR163","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2147\/IDR.S260161","volume":"13","author":"J Shi","year":"2020","unstructured":"Shi J, Su R, Zheng D et al (2020) Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan province. Infect Drug Resist 13:2929\u20132941. https:\/\/doi.org\/10.2147\/IDR.S260161","journal-title":"Infect Drug Resist"},{"key":"3466_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0229040","volume":"15","author":"A Shibabaw","year":"2020","unstructured":"Shibabaw A, Gelaw B, Gebreyes W et al (2020) The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia. PLoS One 15:1\u201313. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0229040","journal-title":"PLoS One"},{"key":"3466_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0068-3","volume":"4","author":"AP Singh","year":"2019","unstructured":"Singh AP, Biswas A, Shukla A, Maiti P (2019) Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther 4:1\u201321. https:\/\/doi.org\/10.1038\/s41392-019-0068-3","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"3466_CR166","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.3390\/ELECTRONICS11172634","volume":"2634","author":"M Singh","year":"2022","unstructured":"Singh M, Pujar GV, Kumar SA et al (2022) Evolution of machine learning in tuberculosis diagnosis: a review of deep learning-based medical applications. Electron 2634(11):2634. https:\/\/doi.org\/10.3390\/ELECTRONICS11172634","journal-title":"Electron"},{"key":"3466_CR167","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.3390\/ELECTRONICS11172634","volume":"11","author":"M Singh","year":"2022","unstructured":"Singh M, Pujar GV, Kumar SA et al (2022) Evolution of machine learning in tuberculosis diagnosis: a review of deep learning-based medical applications. Electron 11:2634\u20132657. https:\/\/doi.org\/10.3390\/ELECTRONICS11172634","journal-title":"Electron"},{"key":"3466_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/OFID\/OFAD177","volume":"10","author":"P Sinha","year":"2023","unstructured":"Sinha P, Jacobson KR, Robert HorsburghJr C, Acu\u00f1a-Villaordu\u00f1a C (2023) At long last: short, all-oral regimens for multidrug-resistant tuberculosis in the United States. Open Forum Infect Dis 10:1\u20138. https:\/\/doi.org\/10.1093\/OFID\/OFAD177","journal-title":"Open Forum Infect Dis"},{"key":"3466_CR169","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1183\/09031936.00145411","volume":"39","author":"A Skrahina","year":"2012","unstructured":"Skrahina A, Hurevich H, Zalutskaya A et al (2012) Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39:1425\u20131431. https:\/\/doi.org\/10.1183\/09031936.00145411","journal-title":"Eur Respir J"},{"key":"3466_CR170","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/82_2012_279","volume":"374","author":"T Smith","year":"2013","unstructured":"Smith T, Wolff KA, Nguyen L (2013) Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol 374:53\u201380. https:\/\/doi.org\/10.1007\/82_2012_279","journal-title":"Curr Top Microbiol Immunol"},{"key":"3466_CR171","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/J.IJID.2016.10.021","volume":"56","author":"G Sotgiu","year":"2017","unstructured":"Sotgiu G, Tiberi S, Centis R et al (2017) Applicability of the shorter \u201cBangladesh regimen\u201d in high multidrug-resistant tuberculosis settings. Int J Infect Dis 56:190\u2013193. https:\/\/doi.org\/10.1016\/J.IJID.2016.10.021","journal-title":"Int J Infect Dis"},{"key":"3466_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2180-14-165","volume":"14","author":"A Sowajassatakul","year":"2014","unstructured":"Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S (2014) Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand. BMC Microbiol 14:1\u20137. https:\/\/doi.org\/10.1186\/1471-2180-14-165","journal-title":"BMC Microbiol"},{"key":"3466_CR173","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1128\/JCM.00168-11","volume":"49","author":"FS Spies","year":"2011","unstructured":"Spies FS, Ribeiro AW, Ramos DF et al (2011) Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol 49:2625\u20132630. https:\/\/doi.org\/10.1128\/JCM.00168-11","journal-title":"J Clin Microbiol"},{"key":"3466_CR174","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/FPHAR.2023.1100488","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler JAM, Maartens G, Meintjes G, Wasserman S (2023) Clofazimine for the treatment of tuberculosis. Front Pharmacol 14:1100488. https:\/\/doi.org\/10.3389\/FPHAR.2023.1100488","journal-title":"Front Pharmacol"},{"key":"3466_CR175","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/PHARMACEUTICS13050592","volume":"13","author":"F Stephanie","year":"2021","unstructured":"Stephanie F, Saragih M, Tambunan USF (2021) Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics 13:592\u2013613. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13050592","journal-title":"Pharmaceutics"},{"key":"3466_CR176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-021-00883-8","volume":"10","author":"W Su","year":"2021","unstructured":"Su W, Ruan YZ, Li T et al (2021) Characteristics of rifampicin-resistant tuberculosis detection in China, 2015\u20132019. Infect Dis Poverty 10:1\u20138. https:\/\/doi.org\/10.1186\/s40249-021-00883-8","journal-title":"Infect Dis Poverty"},{"key":"3466_CR177","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/s0140-6736(02)08830-x","volume":"359","author":"PG Su\u00e1rez","year":"2002","unstructured":"Su\u00e1rez PG, Floyd K, Portocarrero J et al (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359:1980\u20131989. https:\/\/doi.org\/10.1016\/s0140-6736(02)08830-x","journal-title":"Lancet"},{"key":"3466_CR178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12879-020-05749-2\/TABLES\/3","volume":"21","author":"ZZ Sultana","year":"2021","unstructured":"Sultana ZZ, Hoque FU, Beyene J et al (2021) HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 21:1\u201313. https:\/\/doi.org\/10.1186\/S12879-020-05749-2\/TABLES\/3","journal-title":"BMC Infect Dis"},{"key":"3466_CR179","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4236\/JTR.2018.63021","volume":"6","author":"T Tasnim","year":"2018","unstructured":"Tasnim T, Alam FM, Ahmed SMA et al (2018) gyrA gene mutation conferring phenotypic cross-resistance among fluoroquinolones (ofloxacin, levofloxacin and gatifloxacin) in multidrug resistant Mycobacterium tuberculosis strains isolated from pulmonary MDR-TB patients in Bangladesh. J Tuberc Res 6:227\u2013237. https:\/\/doi.org\/10.4236\/JTR.2018.63021","journal-title":"J Tuberc Res"},{"key":"3466_CR180","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4314\/EJHS.V28I3.7","volume":"28","author":"A Tavanaee Sani","year":"2018","unstructured":"Tavanaee Sani A, Ashna H, Kaffash A et al (2018) Mutations of rpob gene associated with rifampin resistance among Mycobacterium tuberculosis isolated in tuberculosis regional reference laboratory in Northeast of Iran during 2015\u20132016. Ethiop J Health Sci 28:299\u2013304. https:\/\/doi.org\/10.4314\/EJHS.V28I3.7","journal-title":"Ethiop J Health Sci"},{"key":"3466_CR181","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/JMDH.S313968","volume":"14","author":"A Tewabe","year":"2021","unstructured":"Tewabe A, Abate A, Tamrie M et al (2021) Targeted drug delivery \u2014 from magic bullet to nanomedicine: principles, challenges, and future perspectives. J Multidiscip Healthc 14:1711\u20131724. https:\/\/doi.org\/10.2147\/JMDH.S313968","journal-title":"J Multidiscip Healthc"},{"key":"3466_CR182","unstructured":"Thomas E Herchline JKA (2020) Tuberculosis (TB). In: MedScape. https:\/\/emedicine.medscape.com\/article\/230802-overview. Accessed 6 Jun 2023"},{"key":"3466_CR183","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.RPPNEN.2017.10.009","volume":"24","author":"S Tiberi","year":"2018","unstructured":"Tiberi S, Mu\u00f1oz-Torrico M, Duarte R et al (2018) New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology 24:86\u201398. https:\/\/doi.org\/10.1016\/J.RPPNEN.2017.10.009","journal-title":"Pulmonology"},{"key":"3466_CR184","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/J.IJID.2022.03.026","volume":"124","author":"S Tiberi","year":"2022","unstructured":"Tiberi S, Utjesanovic N, Galvin J et al (2022) Drug resistant TB \u2013 latest developments in epidemiology, diagnostics and management. Int J Infect Dis 124:S20\u2013S25. https:\/\/doi.org\/10.1016\/J.IJID.2022.03.026","journal-title":"Int J Infect Dis"},{"key":"3466_CR185","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1080\/22221751.2022.2099304","volume":"11","author":"K Trisakul","year":"2022","unstructured":"Trisakul K, Nonghanphithak D, Chaiyachat P et al (2022) High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Emerg Microbes Infect 11:1857\u20131866. https:\/\/doi.org\/10.1080\/22221751.2022.2099304","journal-title":"Emerg Microbes Infect"},{"key":"3466_CR186","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/J.JMII.2013.08.018","volume":"48","author":"ST Tseng","year":"2015","unstructured":"Tseng ST, Tai CH, Li CR et al (2015) The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan. J Microbiol Immunol Infect 48:249\u2013255. https:\/\/doi.org\/10.1016\/J.JMII.2013.08.018","journal-title":"J Microbiol Immunol Infect"},{"key":"3466_CR187","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/JAC\/DKQ322","volume":"65","author":"G Tud\u00f3","year":"2010","unstructured":"Tud\u00f3 G, Rey E, Borrell S et al (2010) Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. J Antimicrob Chemother 65:2341\u20132346. https:\/\/doi.org\/10.1093\/JAC\/DKQ322","journal-title":"J Antimicrob Chemother"},{"key":"3466_CR188","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/J.TUBE.2018.11.006","volume":"114","author":"O Tulyaprawat","year":"2019","unstructured":"Tulyaprawat O, Chaiprasert A, Chongtrakool P et al (2019) Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. Tuberculosis 114:42\u201346. https:\/\/doi.org\/10.1016\/J.TUBE.2018.11.006","journal-title":"Tuberculosis"},{"key":"3466_CR189","unstructured":"Udwadia ZF, Pinto LM, Uplekar MW (2014) Managerial aspects of the programmatic management of drug-resistant TB. In: Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva"},{"key":"3466_CR190","unstructured":"USAID (2016) National action plan for combating multidrug-resistant tuberculosis"},{"key":"3466_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ANTIBIOTICS11020133\/S1","volume":"11","author":"A Ushtanit","year":"2022","unstructured":"Ushtanit A, Kulagina E, Mikhailova Y et al (2022) Molecular determinants of ethionamide resistance in clinical isolates of Mycobacterium tuberculosis. Antibiotics 11:1\u201310. https:\/\/doi.org\/10.3390\/ANTIBIOTICS11020133\/S1","journal-title":"Antibiotics"},{"key":"3466_CR192","doi-asserted-by":"publisher","unstructured":"Vandenesch F, Lemoine J, Becker K, et al (2020) Modern tools for rapid diagnostics of antimicrobial resistance. Front Cell Infect Microbiol | www.frontiersin.org 1:308\u2013330. https:\/\/doi.org\/10.3389\/fcimb.2020.00308","DOI":"10.3389\/fcimb.2020.00308"},{"key":"3466_CR193","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/BIOMEDINFORMATICS3040069\/S1","volume":"3","author":"V Vashisht","year":"2023","unstructured":"Vashisht V, Vashisht A, Mondal AK et al (2023) Genomics for emerging pathogen identification and monitoring: prospects and obstacles. BioMedInformatics 3:1145\u20131177. https:\/\/doi.org\/10.3390\/BIOMEDINFORMATICS3040069\/S1","journal-title":"BioMedInformatics"},{"key":"3466_CR194","doi-asserted-by":"publisher","unstructured":"Vilch\u00e8ze C, Jr WRJ, Author MS (2019) Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities HHS public access author manuscript. Microbiol Spectr 2:1\u201321. https:\/\/doi.org\/10.1128\/microbiolspec.MGM2-0014-2013","DOI":"10.1128\/microbiolspec.MGM2-0014-2013"},{"key":"3466_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MICROBIOLSPEC.MGM2-0014-2013","volume":"2","author":"C Vilch\u00e8ze","year":"2014","unstructured":"Vilch\u00e8ze C, Jacobs JRWR (2014) Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr 2:1\u201321. https:\/\/doi.org\/10.1128\/MICROBIOLSPEC.MGM2-0014-2013","journal-title":"Microbiol Spectr"},{"key":"3466_CR196","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1017\/S095026882100279X","volume":"150","author":"L Wang","year":"2022","unstructured":"Wang L, Yang J, Chen L et al (2022) Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance. Epidemiol Infect 150:e22. https:\/\/doi.org\/10.1017\/S095026882100279X","journal-title":"Epidemiol Infect"},{"key":"3466_CR197","unstructured":"WHO, The Global Fund To Fight AIDS, Tuberculosis and Malaria STP (2019) Frequently asked questions on the WHO Rapid Communication: key changes to the treatment of multidrug-and rifampicin-resistant TB Prepared by the WHO Task Force to support country transition towards new recommendations for the treatment of MDR-TB"},{"key":"3466_CR198","unstructured":"WHO (2011) Guidelines for the programmatic management of drug-resistance tuberculosis. World Heal Organ 1\u201344"},{"key":"3466_CR199","unstructured":"WHO (2014a) Mono- and poly-resistant strains (drug-resistant TB other than MDR-TB). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva, pp 1\u201327"},{"key":"3466_CR200","unstructured":"WHO (2014b) Treatment strategies for MDR-TB and XDR-TB. In: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, pp 75\u201399"},{"key":"3466_CR201","unstructured":"WHO (2014c) Drug-resistant TB and HIV. In: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva"},{"key":"3466_CR202","unstructured":"WHO (2018) Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). In: World Heal. Organ. https:\/\/iris.who.int\/handle\/10665\/275383. Accessed 22 Mar 2024"},{"key":"3466_CR203","unstructured":"WHO (2019) WHO consolidated guidelines on drug-resistant tuberculosis treatment"},{"key":"3466_CR204","unstructured":"WHO (2020) Consolidated operational guidelines on handbook tuberculosis"},{"key":"3466_CR205","unstructured":"WHO (2021a) WHO announces updated definitions of extensively drug-resistant tuberculosis. In: WHO. https:\/\/www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Accessed 5 Jun 2023"},{"key":"3466_CR206","unstructured":"WHO (2021b) WHO announces updated definitions of extensively drug-resistant tuberculosis. In: WHO. https:\/\/www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Accessed 26 May 2023"},{"key":"3466_CR207","unstructured":"WHO (2021c) Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. In: World Heal. Organ. https:\/\/www.who.int\/publications\/i\/item\/9789240018662. Accessed 22 Mar 2024"},{"key":"3466_CR208","unstructured":"WHO (2022a) WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. In: World Heal. Organ. https:\/\/www.who.int\/publications\/i\/item\/9789240063129. Accessed 22 Mar 2024"},{"key":"3466_CR209","unstructured":"WHO (2022b) WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]. Geneva: World Health Organization.\u00a0Recommendations. Available from: https:\/\/ncbi.nlm.nih.gov\/books\/NBK588557\/"},{"key":"3466_CR210","unstructured":"WHO (2023a) Global tuberculosis report 2023"},{"key":"3466_CR211","unstructured":"WHO (2023b) Xpert MTB\/RIF and Xpert MTB\/RIF ultra assays | TB knowledge sharing. In: WHO TB Knowl. Shar. Platf. https:\/\/tbksp.org\/en\/node\/1649. Accessed 22 Mar 2024"},{"key":"3466_CR212","unstructured":"WHO (2023c) 5. The 9-month all-oral regimen. In: WHO TB Knowl. Shar. Platf. https:\/\/tbksp.org\/en\/node\/582. Accessed 6 Jun 2023"},{"key":"3466_CR213","unstructured":"WHO (2024a) Tuberculosis: extensively drug-resistant tuberculosis (XDR-TB). https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/tuberculosis-extensively-drug-resistant-tuberculosis-(XDR-TB). Accessed 7 Aug 2024"},{"key":"3466_CR214","unstructured":"WHO (2024b) New treatment for TB. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\/featured-topics\/new-treatment-tb. Accessed 7 Aug 2024"},{"key":"3466_CR215","unstructured":"WHO (2024c) Roadmap towards ending TB in children and adolescents- Third edition"},{"key":"3466_CR216","unstructured":"WHO (2024d) Tuberculosis: multidrug-resistant (MDR-TB) or rifampicin-resistant TB (RR-TB). https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb). Accessed 7 Aug 2024"},{"key":"3466_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-016-0598-2\/PEER-REVIEW","volume":"14","author":"AA Witney","year":"2016","unstructured":"Witney AA, Cosgrove CA, Arnold A et al (2016) Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC Med 14:1\u20137. https:\/\/doi.org\/10.1186\/S12916-016-0598-2\/PEER-REVIEW","journal-title":"BMC Med"},{"key":"3466_CR218","unstructured":"World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis Guidelines for the programmatic management of drug-resistant tuberculosis. World Heal Organ 12\u2013185"},{"key":"3466_CR219","unstructured":"World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis"},{"key":"3466_CR220","unstructured":"World Health Organization (2016a) WHO treatment guidelines for drug-resistant tuberculosis\u202f: 2016 update."},{"key":"3466_CR221","unstructured":"World Health Organization (2016b) The shorter MDR-TB regimen"},{"key":"3466_CR222","unstructured":"World Health Organization (2018a) WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 1\u201345"},{"key":"3466_CR223","unstructured":"World Health Organization (2018b) Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis 2018"},{"key":"3466_CR224","unstructured":"World Health Organization (2018c) Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis"},{"key":"3466_CR225","unstructured":"World Health Organization (2018d) Rapid communication\u202f: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis. World Heal Organ 1\u20137"},{"key":"3466_CR226","unstructured":"World Health Organization (2020a) Global tuberculosis report 2020"},{"key":"3466_CR227","unstructured":"World Health Organization (2020b) Consolidated guidelines on tuberculosis treatment"},{"key":"3466_CR228","unstructured":"World Health Organization (2022) Global tuberculosis report 2022"},{"key":"3466_CR229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0270003","volume":"17","author":"Y Xi","year":"2022","unstructured":"Xi Y, Zhang W, Qiao RJ, Tang J (2022) Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis. PLoS One 17:1\u201315. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0270003","journal-title":"PLoS One"},{"key":"3466_CR230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/11786361231152438","volume":"16","author":"P Yadav","year":"2023","unstructured":"Yadav P (2023) Challenges & solutions for recent advancements in multi-drugs resistance tuberculosis: a review. Microbiol Insights 16:1\u20139. https:\/\/doi.org\/10.1177\/11786361231152438","journal-title":"Microbiol Insights"},{"key":"3466_CR231","doi-asserted-by":"publisher","unstructured":"Yadav S, Jeyaraman N, Jeyaraman M, Rawal G (2024) Artificial intelligence in tuberculosis diagnosis: revolutionizing detection and treatment. IP Indian J Immunol Respir Med 9:85\u201387. https:\/\/doi.org\/10.18231\/j.ijirm.2024.017","DOI":"10.18231\/j.ijirm.2024.017"},{"key":"3466_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FMOLB.2023.1099654\/BIBTEX","volume":"10","author":"Y Yu","year":"2023","unstructured":"Yu Y, Jiang XX, Li JC (2023) Biomarker discovery for tuberculosis using metabolomics. Front Mol Biosci 10:1\u201323. https:\/\/doi.org\/10.3389\/FMOLB.2023.1099654\/BIBTEX","journal-title":"Front Mol Biosci"},{"key":"3466_CR233","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/CLINPRACT14020030","volume":"14","author":"N Zaporojan","year":"2024","unstructured":"Zaporojan N, Negrean RA, Hodi\u0219an R et al (2024) Evolution of laboratory diagnosis of tuberculosis. Clin Pract 14:388\u2013416. https:\/\/doi.org\/10.3390\/CLINPRACT14020030","journal-title":"Clin Pract"},{"key":"3466_CR234","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/J.JIPH.2018.04.005","volume":"11","author":"MT Zaw","year":"2018","unstructured":"Zaw MT, Emran NA, Lin Z (2018) Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 11:605\u2013610. https:\/\/doi.org\/10.1016\/J.JIPH.2018.04.005","journal-title":"J Infect Public Health"},{"key":"3466_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0300060521997596","volume":"49","author":"MC Zeng","year":"2021","unstructured":"Zeng MC, Jia QJ, Tang LM (2021) rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis isolates from rural areas of Zhejiang, China. J Int Med Res 49:1\u20139. https:\/\/doi.org\/10.1177\/0300060521997596","journal-title":"J Int Med Res"},{"key":"3466_CR236","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1128\/AAC.03695-14","volume":"59","author":"X Zhang","year":"2015","unstructured":"Zhang X, Liu L, Zhang Y et al (2015) Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in Northern China from 2006 to 2012. Antimicrob Agents Chemother 59:1320\u20131324. https:\/\/doi.org\/10.1128\/AAC.03695-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3466_CR237","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.2147\/IDR.S256128","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Liu X, Yang L et al (2020) Barriers and strategies: a review of access to affordable multi-drug resistant tuberculosis medication in China. Infect Drug Resist 13:3679\u20133687. https:\/\/doi.org\/10.2147\/IDR.S256128","journal-title":"Infect Drug Resist"},{"key":"3466_CR238","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/ANTIBIOTICS12081257\/S1","volume":"12","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lu Y, Zhu Y et al (2023) Whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance: a retrospective observational study in Eastern China. Antibiotics 12:1257. https:\/\/doi.org\/10.3390\/ANTIBIOTICS12081257\/S1","journal-title":"Antibiotics"},{"key":"3466_CR239","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/J.JIPH.2024.02.012","volume":"17","author":"F Zhang","year":"2024","unstructured":"Zhang F, Zhang F, Li L, Pang Y (2024) Clinical utilization of artificial intelligence in predicting therapeutic efficacy in pulmonary tuberculosis. J Infect Public Health 17:632\u2013641. https:\/\/doi.org\/10.1016\/J.JIPH.2024.02.012","journal-title":"J Infect Public Health"},{"key":"3466_CR240","doi-asserted-by":"publisher","first-page":"66S","DOI":"10.3855\/jidc.13757","volume":"15","author":"E Zhdanova","year":"2021","unstructured":"Zhdanova E, Goncharova O, Davtyan H et al (2021) 9\u201312 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect Dev Ctries 15:66S-74S. https:\/\/doi.org\/10.3855\/jidc.13757","journal-title":"J Infect Dev Ctries"},{"key":"3466_CR241","doi-asserted-by":"publisher","first-page":"1183597","DOI":"10.3389\/FCIMB.2023.1183597","volume":"13","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou X, Zhuang Z et al (2023) Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children. Front Cell Infect Microbiol 13:1183597. https:\/\/doi.org\/10.3389\/FCIMB.2023.1183597","journal-title":"Front Cell Infect Microbiol"},{"key":"3466_CR242","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2471\/BLT.11.092585","volume":"90","author":"M Zignol","year":"2012","unstructured":"Zignol M, van Gemert W, Falzon D et al (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007\u20132010. Bull World Health Organ 90:111. https:\/\/doi.org\/10.2471\/BLT.11.092585","journal-title":"Bull World Health Organ"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03466-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:48:29Z","timestamp":1742294909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":242,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3466"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03466-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}